The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
As Brainsway pioneers a new option in obsessive compulsive disorder, Vantage looks at how these devices have moved into new indications over the past decade.
Nine IPOs have got away so far this year, and one of them is very big indeed.
In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.